Ownership and insider activity for Bone Biologics Corporation (BBLG): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth.
Price
| Price | $0.54 |
| Market Cap | $1M |
| Exchange | NASDAQ |
| Country | US |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $620375 | $690279 | $955374 | $24145 | 0 | $6.7M | $7.5M | $3.0M | $3.3M | $5.3M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | $579910 | $328844 | 0 | $9895 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $700898 | $795513 | $1.0M | $30827 | 0 | $6.7M | $8.5M | $3.7M | $3.9M | $5.8M |
| Property, Plant & Equipment | $242 | $146 | $50 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $973085 | $795659 | $1.0M | $30827 | 0 | $6.7M | $8.5M | $3.7M | $3.9M | $5.8M |
| Accounts Payable | $226516 | $216903 | $125203 | $42879 | $465396 | $99909 | $104786 | $360662 | $373042 | $417884 |
| Short-term Debt | $1.2M | 0 | $9.0M | 0 | $11.7M | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.5M | $961795 | $9.6M | $578447 | $13.7M | $99909 | $2.5M | $831402 | $377712 | $418587 |
| Long-term Debt | $7.6M | $8.2M | 0 | $11.3M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | $9.6M | $9.2M | $9.6M | $11.9M | $13.7M | $99909 | $2.5M | $831402 | $377712 | $418587 |
| Retained Earnings | -$52.1M | -$59.2M | -$63.6M | -$67.0M | -$68.9M | -$70.5M | -$72.0M | -$80.9M | -$85.0M | -$88.1M |
| Total Equity | -$8.4M | -$8.4M | -$8.6M | -$11.9M | -$13.7M | $6.6M | $5.9M | $2.9M | $3.5M | $5.4M |
| Total Debt | $8.8M | $8.2M | $9.0M | $11.3M | $11.7M | 0 | 0 | 0 | 0 | 0 |
| Net Debt | $8.1M | $7.5M | $8.0M | $11.3M | $11.7M | -$6.7M | -$7.5M | -$3.0M | -$3.3M | -$5.3M |
| Working Capital | -$800918 | -$166282 | -$8.6M | -$547620 | -$13.7M | $6.6M | $5.9M | $2.9M | $3.5M | $5.4M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 8.67 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -19.57 |
Profitability
| Return on Equity | -57.85% |
| Return on Invested Capital | -78.01% |
| Return on Assets | -65.16% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: BDRX · DHAI · GCTK · HSCS · INM · MOVE · NAOV
Explore sector: Healthcare · Biotechnology
More sections of BBLG: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks